RxDoctor Payments Data

Sherry Miller, PA

Physician Assistant · Hazard, KYNPI 1184604878

Payments from drug & device makers

$5,763in general payments, 2019–2025

Across 259 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$885
  • Novo Nordisk$474
  • Boehringer Ingelheim$451
  • Pfizer$402
  • AbbVie$339
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$1,10319%
  • Food & beverage$4,65981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,763 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,308
Medicare patients
84
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$47,230
FarxigaDapagliflozin Propanediol52$43,461
MounjaroTirzepatide26$26,091
EliquisApixaban30$24,989
TrulicityDulaglutide18$20,577
JanuviaSitagliptin Phosphate21$19,152
JardianceEmpagliflozin19$18,101
EntrestoSacubitril/Valsartan20$12,956
VascepaIcosapent Ethyl22$11,526
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$10,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$6,460
Humalog Kwikpen U-100Insulin Lispro24$4,179
Insulin Lispro Kwikpen U-100Insulin Lispro20$2,934
Insulin Lispro16$2,339
Colesevelam Hcl13$1,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$885$54,14965 claims
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$286$49,00660 claims
Novo NordiskOzempic$474$47,23047 claims
PfizerEliquis$402$24,98930 claims
MerckJanuvia$43$19,15221 claims
Boehringer IngelheimJardiance$451$18,10119 claims
AbbVieSynthroid$339$64213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →